Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Digital health mergers and acquisitions (M&A) along with venture capital (VC) activities are rapidly increasing. Tempus AI's $1.7 billion acquisition of Personalis is part of a larger trend that is influencing health system operators’ selection of vendors. With $7.4 billion in funding during the first half of 2026, the health-tech industry is undergoing significant transformation.

  • 01Tempus AI acquired Personalis for $1.7 billion.
  • 02Health-tech received $7.4 billion in funding in the first half of 2026.
  • 03M&A activities are influencing vendor choices for health system operators.

Jul 30, 2026

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

In the first half of 2026, digital health AI investments reached $7.4 billion as organizations like CMS, hospitals, and startups increased their adoption of AI. Significant moves include the establishment of a new CMS technology office and a $1.7 billion acquisition in cancer technology. These developments mark an enterprise-level commitment to advancing AI in healthcare.

  • 01Digital health AI investments reached $7.4 billion in H1 2026.
  • 02The CMS established a new technology office to advance healthcare AI.
  • 03A major acquisition in cancer technology totaled $1.7 billion.

Jul 30, 2026

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

The global structural health monitoring (SHM) market is projected to surpass $8.6 billion by 2035. This growth is fueled by the integration of AI analytics, wireless sensor technologies, and the necessity to address aging infrastructure. The expansion reflects a widespread adoption of these technologies in various sectors.

  • 01The SHM market is expected to exceed $8.6 billion by 2035.
  • 02Advancements in AI-powered analytics and wireless sensors are key drivers of market growth.
  • 03Aging infrastructure is creating a demand for enhanced structural health monitoring solutions.

Jul 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512